Actinium Pharmaceuticals, Inc. (ATNM) stock
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)
Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –
Actinium Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Actinium Pharmaceuticals's profit margin for the twelve months ending Dec 31, 2025 was -37652.2%. For fiscal 2025 it was -37652.2%, against -60269.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -37652.2% | +22616.9 |
| FY2023 | Dec 31, 2023 | -60269.1% | −57063.6 |
| FY2022 | Dec 31, 2022 | -3205.5% | −1040.0 |
| FY2021 | Dec 31, 2021 | -2165.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 79.7% | +625.4 |
| Q3 FY2025 | Sep 30, 2025 | -5701.1% | +29125.0 |
| Q3 FY2022 | Sep 30, 2022 | -21053.3% | −18296.7 |
| Q2 FY2022 | Jun 30, 2022 | -17260.0% | −15372.4 |
| Q1 FY2022 | Mar 31, 2022 | -545.6% | +309.7 |
| Q4 FY2021 | Dec 31, 2021 | -34826.1% | – |
| Q3 FY2021 | Sep 30, 2021 | -2756.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -1887.6% | – |
| Q1 FY2021 | Mar 31, 2021 | -855.3% | – |
See a number that looks wrong?